PMID- 36100063
OWN - NLM
STAT- MEDLINE
DCOM- 20221205
LR  - 20230308
IS  - 1535-7732 (Electronic)
IS  - 1051-0443 (Linking)
VI  - 33
IP  - 12
DP  - 2022 Dec
TI  - Factors Affecting Adverse Events after Venous Malformation Sclerotherapy.
PG  - 1548-1557
LID - S1051-0443(22)01186-1 [pii]
LID - 10.1016/j.jvir.2022.09.001 [doi]
AB  - PURPOSE: To evaluate factors that contribute to adverse events (AEs) after 
      embolization of venous malformations (VMs) using sclerosing agents. MATERIALS AND 
      METHODS: A retrospective review of patients who underwent direct puncture 
      embolization of VMs with a sclerosing agent and adjunctive techniques, also 
      termed as sclerotherapy, from 2016 to 2021 was performed. Three-hundred one 
      embolizations in 137 patients (median age, 19.0 years; interquartile range, 
      12.8-31.5 years) were evaluated. The VM characteristics and embolization details 
      were analyzed. Anticoagulation was also evaluated based on D-dimer levels. 
      Cutaneous and noncutaneous AEs were analyzed. The AEs were categorized using 
      Society of Interventional Radiology guidelines. RESULTS: VMs involving tissue 
      planes were subcutaneous (n = 104), intramuscular (n = 84), and combined (n = 
      113). Overlying skin involvement was observed in 56% of the patients. Sodium 
      tetradecyl sulfate was mainly used (83%). Periprocedural anticoagulation was used 
      in 9% of the patients. Most AEs were minor (30/301, 9.7%), and only 1.7% (5/301) 
      were major (21 cutaneous and 14 noncutaneous AEs). Age below 18 years (odds 
      ratio, 4.4502; 95% confidence interval, 1.5607-12.6890; P = .0052) and overlying 
      skin involvement (odds ratio, 7.1794; 95% confidence interval, 1.6226-31.7656; 
      P = .0094) were factors associated with cutaneous AEs. All noncutaneous AEs 
      developed in patients with intramuscular VMs; however, this association was not 
      statistically significant. There was no severe hematologic AE or permanent 
      consequence. CONCLUSIONS: The overall AE rate after VM embolization was 11.6%; 
      however, major AEs were rare (1.7%). Cutaneous AEs were associated with young age 
      and overlying skin involvement. All noncutaneous AEs developed in patients with 
      intramuscular VMs.
CI  - Copyright (c) 2022 SIR. Published by Elsevier Inc. All rights reserved.
FAU - Lee, Sang Yub
AU  - Lee SY
AD  - Department of Radiology and Center for Imaging Science, Samsung Medical Center, 
      Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
FAU - Kim, Kyung Rae
AU  - Kim KR
AD  - Department of Radiology, School of Medicine, University of North Carolina at 
      Chapel Hill, Chapel Hill, North Carolina. Electronic address: 
      kyung_kim@med.unc.edu.
LA  - eng
PT  - Journal Article
DEP - 20220912
PL  - United States
TA  - J Vasc Interv Radiol
JT  - Journal of vascular and interventional radiology : JVIR
JID - 9203369
RN  - 0 (Sclerosing Solutions)
RN  - Q1SUG5KBD6 (Sodium Tetradecyl Sulfate)
RN  - 0 (Anticoagulants)
SB  - IM
MH  - Humans
MH  - Young Adult
MH  - Adult
MH  - Adolescent
MH  - *Sclerotherapy/adverse effects/methods
MH  - Sclerosing Solutions/adverse effects
MH  - Sodium Tetradecyl Sulfate/adverse effects
MH  - *Vascular Malformations/diagnostic imaging/therapy
MH  - Retrospective Studies
MH  - Anticoagulants/adverse effects
MH  - Treatment Outcome
EDAT- 2022/09/14 06:00
MHDA- 2022/12/06 06:00
CRDT- 2022/09/13 19:14
PHST- 2022/03/13 00:00 [received]
PHST- 2022/08/15 00:00 [revised]
PHST- 2022/09/02 00:00 [accepted]
PHST- 2022/09/14 06:00 [pubmed]
PHST- 2022/12/06 06:00 [medline]
PHST- 2022/09/13 19:14 [entrez]
AID - S1051-0443(22)01186-1 [pii]
AID - 10.1016/j.jvir.2022.09.001 [doi]
PST - ppublish
SO  - J Vasc Interv Radiol. 2022 Dec;33(12):1548-1557. doi: 10.1016/j.jvir.2022.09.001. 
      Epub 2022 Sep 12.